Advancing Knowledge,
Improving Patient Outcomes

AcademicCME is a jointly accredited healthcare solutions medical education company designed to impact practice behavior by providing clinicians with multi-format educational resources in various therapeutic areas. Our mission is to improve patient outcomes through practical, customized and comprehensive continuing education.

CE Courses

Review of Clinical Trial and Real-World Data for DOAC and other Anticoagulation Therapeutics for VTE

Program Overview

This 0.5-hour, Whiteboard Animation Webcast is designed to review clinical trial and deal-world data for DOAC and other anticoagulation therapeutics for VTE. A majority of new diagnoses of VTE are made by primary care professionals. Evidence-based guidelines for the management of VTE include the most recent updates from the American Society of Hematology (ASH, 2020), the European Society ...
View Course
Update for Hospital and Health-System Pharmacists on Newer Therapeutics to Optimize Management of Patients with Generalized Myasthenia Gravis

Program Overview

About 85% of patients with generalized myasthenia gravis (gMG)--an autoimmune disease of the neuromuscular junction caused by antibodies that attack components of the postsynaptic membrane, impair neuromuscular transmission, and therefore cause weakness and fatigue of skeletal and bulbar muscles--have demonstrable IgG autoantibodies.  These autoantibodies exert a direct pathogenic effect that results in impaired neuromuscular transmission.  Most currently available ...
View Course
Strategies to Address Unmet Needs and Care Delivery Disparities in the Management of Patients with Anemia Associated with Dialysis-Dependent Chronic Kidney Disease

Program Overview

Many CKD patients also experience complex and compounding burdens of disease, particularly once they progress to the stage of requiring hemodialysis. This notably includes anemia (aCKD), which is associated with a reduced quality of life and increased morbidity and mortality. Encouraging clinical trial data have recently emerged for hypoxia-inducible, factor prolyl hydroxylase inhibitor (HIF-PHI) therapeutics for patients on ...
View Course
Clinical Update for Individualized Treatment Plans for Patients with Generalized Myasthenia Gravis

Program Overview

Patients with generalized myasthenia gravis (gMG) experience significant and heterogeneous symptomatology, placing a substantial burden on their quality of life including physical, emotional, and work/financial aspects. Recent clinical trial data are showing that the utilization of individualized dosing including holding treatment during periods of stability can be effective and safe. It is important for clinicians to assess these ...
View Course
Accurate Diagnosis and Guideline-Driven Individualized Treatment Plans to Manage Patients with Non-Tuberculous Mycobacterial Lung Disease

Program Overview

This program is derived from a lecture delivered at the 2023 Eastern Pulmonary Conference. The expert faculty, Drs. Reynold A. Panettieri Jr. and Anne E. O’Donnell, will highlight recent advances in the treatment and management of patients with non-tuberculous mycobacterial lung disease. The faculty will utilize a case-based approach to analyze current clinical trial data of amikacin-based inhalation ...
View Course
Improving Systematic Monitoring for Glucocorticoid Adverse Events to Guide Appropriate Use of Steroid-Sparing Therapy in Patients with gMG

Program Overview

Myasthenia gravis is one of the oldest recognized autoimmune neurologic diseases, but practice-changing clinical trials remain challenging despite greater knowledge of pathophysiology. Both incidence and prevalence of the disease have increased over the years because of greater awareness of MG, better application of diagnostic testing, and better quality of epidemiologic studies. Corticosteroids were introduced as treatment for MG in ...
View Course

Upcoming Events

Advanced Curriculum for Multiple Sclerosis 2024

February 27th, 2024

ACTRIMS Forum 2024

February 29th – March 2nd, 2024

Georgia Neurological Society Annual Meeting

March 22nd – 23rd, 2024

San Francisco Neurological Society Annual Meeting

March 22nd – 24th, 2024

Leave a Reply

Your email address will not be published. Required fields are marked *